A Phase 4 interventional study of Interferon-beta-1a and methylprednisolone in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-09-16.
Sponsored by Biogen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 16th largest by enrollment, is one of 3 that started in 2003, is one of 13 in phase 4, and was the 8th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 80 across the 21 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 8 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 48th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2003, is one of 21 in phase 4, and was the 11th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to find out if Interferon-beta (IFN-beta) can recover its effectiveness after a washout period in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta
This is an explorative multi-centre, open label, non-comparative trial investigating whether it is possible to recover IFN-beta efficacy in breakthrough relapsing-remitting multiple sclerosis patients with high titres of neutralizing IFN-beta antibodies.
Prior to enrollment, treated MS subjects must have been on interferon-beta-1a or interferon-beta-1b for a minimum of 12 months and have reduced bioavailability as defined by the relative expression of MxA mRNA/GAPDH.
Subjects will complete a washout period with concurrent methylprednisolone 500mg PO daily for 3 days every month until they become Neutralizing Antibody negative. Subjects will then be challenged with AVONEX 30mcg IM weekly. Bioavailability will be measured every three months to determine return of biological activity. Clinical and MRI parameters, safety and tolerability will be compared to baseline to determine efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Interferon-beta-1a · Drug: methylprednisolone
dosage and frequency as per Biogen Idec protocol
Also known as: Avonex
dosage and frequency as per Biogen Idec protocol
return of bioavailability of AVONEX (interferon-beta-1a) as measured by induction of MxA mRNA
Time frame: screening and every 3 months from month 6 to month 27
Proportion of patients becoming neutralizing antibody negative
Time frame: screening and every 3 months from month 3 to month 27
proportion of patients becoming neutralizing antibody positive after treatment with AVONEX
Time frame: at baseline and every three months
proportion of patents relapse free
Time frame: months 6, 12, 18 and 24
total relapses
Time frame: 27 months
proportion of patients with an increase in EDSS of 1 point
Time frame: screening, 3, 9, 15, 21, and 27 months
Brain atrophy and cumulative number of enlarging T2 lesions on MRI
Time frame: months 0, 12, and 27
The record gives a start of Oct 2003, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Interferon beta-1a · Methylprednisolone
Multiple Sclerosis, Relapsing-Remitting →